Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-29 20:54 | 2026-01-28 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $3.57 | 6,500 | $23,186 | 0 |
| 2026-01-30 03:32 | 2026-01-28 | AIMD | Ainos Inc. | Taiwan Carbon Nano Technology Corp | 10% owner | SELL | $2.17 | 46,000 | $99,806 | 989,925 |
| 2026-01-29 01:01 | 2026-01-26 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $4.98 | 19,274 | $96,044 | 580,329 |
| 2026-01-29 00:30 | 2026-01-26 | LQDA | Liquidia Corp | Boyle Dana | Officer | SELL | $41.65 | 1,580 | $65,807 | 178,848 |
| 2026-01-29 00:30 | 2026-01-26 | LQDA | Liquidia Corp | Adair Jason | Officer | SELL | $41.65 | 688 | $28,655 | 211,169 |
| 2026-01-29 04:19 | 2026-01-26 | HRMY | Harmony Biosciences Holdings, Inc. | Kapadia Sandip | Officer | SELL | $37.15 | 3,746 | $139,171 | 24,521 |
| 2026-01-29 02:07 | 2026-01-26 | JNJ | JOHNSON & JOHNSON | Duato Joaquin | Director, Officer | SELL | $221.23 | 100,000 | $22,122,890 | 30,852 |
| 2026-01-29 02:30 | 2025-12-15 | MIST | Milestone Pharmaceuticals Inc. | Nelson Jeffrey Edward | Officer | OPT+S | $2.25 | 70,252 | $158,208 | 49,848 |
| 2026-01-29 02:30 | 2025-12-15 | MIST | Milestone Pharmaceuticals Inc. | Bharucha David | Officer | OPT+S | $2.25 | 70,252 | $158,208 | 113,181 |
| 2026-01-29 02:30 | 2025-12-15 | MIST | Milestone Pharmaceuticals Inc. | Hasija Amit | Officer | OPT+S | $2.25 | 70,252 | $158,208 | 99,848 |
| 2026-01-29 02:30 | 2025-12-15 | MIST | Milestone Pharmaceuticals Inc. | Muller Lorenz | Officer | OPT+S | $2.25 | 64,746 | $145,853 | 205,406 |
| 2026-01-29 02:30 | 2025-12-15 | MIST | Milestone Pharmaceuticals Inc. | Oliveto Joseph | Director, Officer | OPT+S | $2.24 | 167,577 | $375,322 | 482,744 |
| 2026-01-29 00:31 | 2026-01-20 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $470.03 | 30,375 | $14,277,113 | 0 |
| 2026-01-29 00:30 | 2026-01-20 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $464.66 | 14,625 | $6,795,626 | 0 |
| 2026-01-28 01:38 | 2026-01-23 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | Officer | OPT+S | $33.29 | 72,572 | $2,415,842 | 24,353 |
| 2026-01-28 00:30 | 2026-01-26 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | Officer | OPT+S | $96.19 | 842 | $80,994 | 3,700 |
| 2026-01-28 00:30 | 2026-01-26 | MIRM | Mirum Pharmaceuticals, Inc. | Radovich Peter | Officer | OPT+S | $96.19 | 3,143 | $302,331 | 23,286 |
| 2026-01-28 00:30 | 2026-01-26 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | Director, Officer | OPT+S | $96.19 | 6,831 | $657,088 | 169,402 |
| 2026-01-28 04:25 | 2026-01-23 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | Director, Officer | OPT+S | $30.09 | 60,000 | $1,805,136 | 419,173 |
| 2026-01-28 05:35 | 2026-01-27 | KURA | Kura Oncology, Inc. | Burrows Francis | Officer | SELL | $8.46 | 1,311 | $11,092 | 32,424 |
| 2026-01-28 05:35 | 2026-01-27 | KURA | Kura Oncology, Inc. | Powl Brian T. | Officer | SELL | $8.46 | 6,414 | $54,266 | 183,275 |
| 2026-01-28 05:35 | 2026-01-27 | KURA | Kura Oncology, Inc. | FORD KATHLEEN | Officer | SELL | $8.46 | 1,813 | $15,339 | 153,560 |
| 2026-01-28 05:35 | 2026-01-27 | KURA | Kura Oncology, Inc. | Leoni Mollie | Officer | SELL | $8.46 | 8,180 | $69,209 | 267,274 |
| 2026-01-28 05:35 | 2026-01-27 | KURA | Kura Oncology, Inc. | DOYLE THOMAS JAMES | Officer | SELL | $8.46 | 7,142 | $60,426 | 145,167 |
| 2026-01-28 05:35 | 2026-01-27 | KURA | Kura Oncology, Inc. | Bair Teresa Brophy | Officer | SELL | $8.46 | 11,208 | $94,828 | 226,931 |
| 2026-01-28 05:20 | 2026-01-27 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer | OPT+S | $83.13 | 46,203 | $3,841,036 | 60,320 |
| 2026-01-28 05:19 | 2026-01-23 | PTGX | Protagonist Therapeutics, Inc | MOLINA ARTURO MD | Officer | OPT+S | $82.30 | 23,151 | $1,905,306 | 84,115 |
| 2026-01-28 00:14 | 2026-01-23 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Director | BUY | $68.48 | 131,425 | $8,999,984 | 459,010 |
| 2026-01-28 00:30 | 2026-01-26 | MIRM | Mirum Pharmaceuticals, Inc. | BJERKHOLT ERIC | Officer | OPT+S | $96.19 | 1,053 | $101,290 | 43,741 |
| 2026-01-28 05:21 | 2026-01-23 | PTGX | Protagonist Therapeutics, Inc | PATEL DINESH V PH D | Director, Officer | OPT+S | $84.18 | 48,273 | $4,063,742 | 574,505 |
| 2026-01-28 00:15 | 2026-01-23 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $40.55 | 1,235 | $50,084 | 15,445 |
| 2026-01-27 00:35 | 2026-01-22 | ABEO | Abeona Therapeutics Inc. | Vasanthavada Madhav | Officer | SELL | $5.29 | 12,610 | $66,658 | 318,619 |
| 2026-01-27 00:34 | 2026-01-22 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Director, Officer | SELL | $18.10 | 3,828 | $69,296 | 210,164 |
| 2026-01-27 00:33 | 2026-01-22 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | Officer | OPT+S | $18.15 | 1,882 | $34,162 | 145,355 |
| 2026-01-27 00:10 | 2026-01-23 | RPRX | Royalty Pharma plc | Urist Marshall | Officer | SELL | $40.26 | 20,000 | $805,110 | 20,000 |
| 2026-01-26 16:02 | 2026-01-23 | ABT | Abbott Laboratories | Ford Robert B | Director, Officer | BUY | $107.13 | 18,800 | $2,013,967 | 216,203 |
| 2026-01-27 01:38 | 2026-01-26 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Huntsman Carole | Officer | SELL | $493.78 | 910 | $449,339 | 9,122 |
| 2026-01-27 01:14 | 2026-01-26 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Sibold William John | Director, Officer | SELL | $492.42 | 1,577 | $776,546 | 148,497 |
| 2026-01-27 01:05 | 2026-01-26 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Taub Rebecca | Director | SELL | $492.42 | 647 | $318,596 | 452,704 |
| 2026-01-27 01:24 | 2026-01-22 | SION | Sionna Therapeutics, Inc. | TPG GP A, LLC | 10% owner | SELL | $40.00 | 250,000 | $10,000,000 | 6,494,962 |
| 2026-01-24 01:51 | 2026-01-22 | IONS | IONIS PHARMACEUTICALS INC | Devers Shannon L. | Officer | SELL | $81.34 | 3,977 | $323,490 | 22,541 |
| 2026-01-24 00:31 | 2026-01-21 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | Officer | OPT+S | $110.15 | 15,000 | $1,652,177 | 59,634 |
| 2026-01-24 01:33 | 2026-01-22 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $5.30 | 18,221 | $96,659 | 599,603 |
| 2026-01-24 00:48 | 2026-01-20 | RPRX | Royalty Pharma plc | Coyne Terrance P. | Officer | SELL | $39.35 | 69,582 | $2,737,940 | 36,010 |
| 2026-01-24 01:30 | 2026-01-22 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | Officer | OPT+S | $93.33 | 926 | $86,419 | 3,042 |
| 2026-01-23 21:34 | 2026-01-21 | EWTX | Edgewise Therapeutics, Inc. | Edris Badreddin | Director | OPT+S | $29.44 | 115,471 | $3,399,466 | 19,820 |
| 2026-01-24 01:30 | 2026-01-22 | MIRM | Mirum Pharmaceuticals, Inc. | Quan Joanne | Officer | OPT+S | $93.33 | 1,822 | $170,039 | 12,817 |
| 2026-01-24 01:30 | 2026-01-22 | MIRM | Mirum Pharmaceuticals, Inc. | Radovich Peter | Officer | OPT+S | $93.33 | 2,382 | $222,301 | 20,679 |
| 2026-01-24 01:30 | 2026-01-22 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | Director, Officer | OPT+S | $93.33 | 7,098 | $662,422 | 163,733 |
| 2026-01-24 01:34 | 2026-01-21 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Officer | SELL | $72.45 | 4,895 | $354,643 | 31,599 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.